In the News: November 24-30

Sg2 is dedicated to helping our clients interpret the latest news and trends in health care. Below you’ll find our analysis of this week’s key industry headlines, along with links to related Sg2 resources.

JAMA: Adverse Drug Effects Account for 4 of Every 1,000 ED Visits

According to a recent JAMA study, about 4 of every 1,000 ED visits result from adverse drug effects, most commonly due to anticoagulants, antibiotics, diabetes agents and opioid analgesics.

Precision (or personalized) medicine is rapidly gaining traction as a solution to minimize adverse drug reactions by tailoring drug therapies to a patient’s DNA. Genetic profiling ensures that patients receive the right drug, at the proper dosage and in a timely manner.

To learn more about precision medicine programs, watch Sg2’s on-demand webinar on the 2016 Medicine landscape.

mHealth Survey Shows Strong ROI and Anticipated Growth Despite Budget Headwinds

A recent Red Hat study, commissioned with research firm Vanson Bourne, investigated the successes and challenges of mobile health strategies. Researchers found that 82% of surveyed health care organizations have a fully implemented mobile strategy, with nearly 80% reporting positive ROI from mobile app investments. The research involved 200 IT executives from organizations spanning from life sciences, pharmaceuticals, private health care and public health care in the US, UK, France and Germany.

To achieve virtual health’s full potential, organizations need to take the next step, from scattered pilots to fully integrated programs that align with and support enterprise priorities. Read this Sg2 publication to learn more about effective execution in virtual health.

Virginia Expands Access to Naloxone

On November 21, Virginia State Health Commissioner Marissa J Levine, MD, MPH, declared the state’s opioid addiction crisis a public health emergency. As part of the state’s efforts to address this crisis, Levine has issued a standing order that expands access to naloxone, a drug used to treat narcotic overdoses.

In response to the opioid and heroin addiction epidemic, the Comprehensive Addiction and Recovery Act of 2016 was signed into law with bipartisan support. While the law continues to face funding hurdles, Sg2 experts recommend that providers take some fundamental actions today to positively impact this patient population.

  • Share
  • Follow Sg2 on Facebook
  • Follow Sg2 on Twitter
  • Connect with Sg2 on LinkedIn
"Analytics and expertise to help you understand market dynamics and capitalize opportunities for growth."

As of February 11, 2016, Vizient, Inc. has completed its purchase of MedAssets Sg2 and spend and clinical resource management segments from Pamplona Capital Management, LLC. MedAssets revenue cycle business will continue to operate as a wholly-owned subsidiary of Pamplona Capital Management LLP.

Follow Sg2 on Twitter Connect with Sg2 on LinkedIn Watch Sg2 on YouTube